"Vitality Biopharma Inc filed an international patent application in March of 2017 that describes compounds discovered to be effective in a drug screening model of neural repair. The underlying patent rights are based on work performed by the Myelin Repair Foundation (MRF), a non-profit disease research organization that was dedicated to developing regenerative therapies for multiple sclerosis. Researchers discovered several investigational and FDA-approved drugs that are useful in effecting remyelination, a form of nervous system regeneration. The discoveries included a compound called Cannabidiol (CBD), that is known to have a positive track record of safety in clinical trials and to provide pain relief through modulation of the vanilloid TRPV1 receptor. As a result, Vitality Biopharma has made broad patent claims covering use of CBD and other TRPV1 agonists for myelin repair and for treatment of demyelinating disorders."
Cannabinol is the non-psychoactive component of marijuana.
Definitely a good options for pain relief at the very least. Finally here in Canada, we are able to get our license to possess. It is however expensive.
I'm a bit confused. Dr. Ali Fatemi of Kennedy Krieger Institute has stated that adults with adrenomyeloneuropathy do not show any demyelination in the brain. Because of this, how would remyelinating drugs benefit us? I apologize for my lack of understanding.
I believe that is what the current research indicates, monkeybus. So for those of us who never progress into adult cerebral ALD, I suppose there is no benefit to remyelinating drugs. Of course, there would be tremendous benefit for both boys and men with cerebral ALD, so I am encouraged that they are looking at possible treatments.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.